Journal
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
Volume 23, Issue -, Pages S15-S22Publisher
ELSEVIER SCI LTD
DOI: 10.1016/S1521-690X(09)70004-1
Keywords
Cushing's syndrome; Cushing's disease; adrenocorticotrophic hormone (ACTH); pituitary
Categories
Funding
- NEON
- Novartis Pharma
- National Institute for Health Research [NF-SI-0508-10356] Funding Source: researchfish
Ask authors/readers for more resources
Cushing's disease results from prolonged overexposure of tissues to endogenous glucocorticoids, secondary to adrenocorticotrophin excess from the pituitary. Common clinical signs and symptoms include weight gain, hypertension, and osteoporosis. Effective treatment of Cushing's disease can normalize biochemical levels, reverse comorbidities, and improve overall survival and quality of life. Treatment options include pituitary or adrenal surgery, radiotherapy, and various medical therapies, but each has important limitations. Medical therapies that effectively target the pituitary tumour are urgently needed. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available